Market Cap 151.57M
Revenue (ttm) 0.00
Net Income (ttm) -30.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 226,762
Avg Vol 621,930
Day's Range N/A - N/A
Shares Out 63.68M
Stochastic %K 51%
Beta -0.05
Analysts Strong Sell
Price Target $7.87

Company Profile

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to dev...

Industry: Biotechnology
Sector: Healthcare
Phone: 813 875 6600
Address:
10500 University Center Drive, Suite 110, Tampa, United States
2TrustHim
2TrustHim Jul. 13 at 6:59 PM
$HURA Is $2.60 Coming Back Before Close?
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 9 at 9:43 PM
$HURA Current Stock Price: $2.35
0 · Reply
2TrustHim
2TrustHim Jul. 9 at 8:27 PM
$HURA Form ARS!!!
2 · Reply
hhhhfdf
hhhhfdf Jul. 9 at 5:58 PM
$HURA Any updates, about new orphan drug status?
0 · Reply
TuHURA_IR
TuHURA_IR Jul. 6 at 2:42 PM
$HURA Our planned Phase 1b/2 study of TBS-2025 in AML combines two phases of clinical development into a single integrated trial. Dr. Craig Tendler, CMO consultant overseeing the TBS-2025 development program and TuHURA Board member, described the design in the June 15 announcement: "The FDA provided valuable feedback and comprehensive guidance on trial design, which we incorporated into our proposed Phase 1b dose optimization trial. Our plan is to combine the Phase 1b with the Phase 2 study for a combination study design that is much more efficient and could potentially save 4-6 months in development time." We anticipate FDA written responses in July 2026 and, depending on those responses, are targeting initiation of the trial in the second half of 2026.
0 · Reply
Gotsomescrewsmissing
Gotsomescrewsmissing Jul. 4 at 1:21 PM
$PLUG $FLY $HURA worth watching Texas Stock Exchange to launch trading Monday https://share.google/LyvdsxhtkUclEjNQJ
0 · Reply
TuHURA_IR
TuHURA_IR Jul. 2 at 1:52 PM
$HURA In AML patients with NPM1 mutations, VISTA expression has been associated with low response rates of short duration following current therapies, including recently approved menin inhibitors. The June 15 IND filing for TBS-2025 is designed to study whether blocking VISTA can change those outcomes. As President and CEO Dr. James Bianco described in the announcement: "Currently, there are no approved or effective treatment options for these patient populations, representing a significant unmet medical need." We are targeting initiation of the Phase 1b/2 study in the second half of 2026, following FDA written responses anticipated in July 2026.
0 · Reply
TuHURA_IR
TuHURA_IR Jun. 30 at 8:48 PM
$HURA Our pipeline now extends from Merkel Cell Carcinoma into AML and other blood-related cancers, with TBS-2025 targeting VISTA-driven immune evasion alongside our ongoing IFx-2.0 program. On June 15, we filed an Investigational New Drug application with the FDA for TBS-2025, our VISTA-inhibiting antibody, in molecularly defined subsets of acute myeloid leukemia (AML) and other blood-related cancers. The IND covers patients with NPM1 mutations and, in the future, those with FLT3-ITD mutations. It will also enroll patients with relapsed/refractory high-risk myelodysplasia (MDS), where VISTA expression has been associated with low response rates. This filing advances our development in a setting of significant unmet medical need.
0 · Reply
AdityaP
AdityaP Jun. 29 at 3:31 PM
$HURA ESMO
0 · Reply
StocksandRealEstate
StocksandRealEstate Jun. 29 at 12:43 PM
$HURA cmon you dirty dog
0 · Reply
Latest News on HURA
TuHURA Biosciences Proxy statement: Proxy filing

Jul 9, 2026, 8:00 AM EDT - 6 days ago

TuHURA Biosciences Proxy statement: Proxy filing


TuHURA Biosciences Proxy statement: Proxy filing

Jul 9, 2026, 8:00 AM EDT - 6 days ago

TuHURA Biosciences Proxy statement: Proxy filing


TuHURA Biosciences Proxy statement: Proxy filing

Jun 26, 2026, 8:00 AM EDT - 19 days ago

TuHURA Biosciences Proxy statement: Proxy filing


TuHURA Biosciences Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

TuHURA Biosciences Earnings release: Q1 2026


TuHURA Biosciences Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

TuHURA Biosciences Quarterly report: Q1 2026


TuHURA Biosciences Slides: Corporate presentation

May 15, 2026, 7:00 AM EDT - 2 months ago

TuHURA Biosciences Slides: Corporate presentation


TuHURA Biosciences initiated with an Outperform at Citizens

2026-04-27T08:45:56.000Z - 2 months ago

TuHURA Biosciences initiated with an Outperform at Citizens


TuHURA Biosciences initiated with a Buy at Rodman & Renshaw

2026-04-15T12:20:48.000Z - 3 months ago

TuHURA Biosciences initiated with a Buy at Rodman & Renshaw


TuHURA Biosciences Earnings release: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 3 months ago

TuHURA Biosciences Earnings release: Q4 2025


TuHURA Biosciences Annual report: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 3 months ago

TuHURA Biosciences Annual report: Q4 2025


TuHURA Biosciences announces release of Kintara’s CVR

2025-12-15T13:06:01.000Z - 7 months ago

TuHURA Biosciences announces release of Kintara’s CVR


TuHURA Biosciences provides updates across portfolio

2025-12-11T12:35:31.000Z - 7 months ago

TuHURA Biosciences provides updates across portfolio


TuHURA Biosciences announces $15.6M registered direct offering

2025-12-09T14:55:32.000Z - 7 months ago

TuHURA Biosciences announces $15.6M registered direct offering


TuHURA Biosciences price target lowered to $8 from $15 at Maxim

2025-11-14T17:20:32.000Z - 8 months ago

TuHURA Biosciences price target lowered to $8 from $15 at Maxim


TuHURA Biosciences Earnings release: Q3 2025

Nov 14, 2025, 7:00 AM EST - 8 months ago

TuHURA Biosciences Earnings release: Q3 2025


TuHURA Biosciences Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 8 months ago

TuHURA Biosciences Quarterly report: Q3 2025


TuHURA Biosciences files $250M mixed securities shelf

2025-11-03T22:35:14.000Z - 9 months ago

TuHURA Biosciences files $250M mixed securities shelf


TuHURA Biosciences Registration statement: Registration filing

Nov 3, 2025, 7:00 AM EST - 9 months ago

TuHURA Biosciences Registration statement: Registration filing


TuHURA Biosciences Registration statement: Registration filing

Sep 18, 2025, 8:00 AM EDT - 10 months ago

TuHURA Biosciences Registration statement: Registration filing


TuHURA Biosciences Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 11 months ago

TuHURA Biosciences Earnings release: Q2 2025


TuHURA Biosciences Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 11 months ago

TuHURA Biosciences Quarterly report: Q2 2025


TuHURA Biosciences included in Russell 3000 and 2000 Indexes

2025-07-01T12:55:33.000Z - 1 year ago

TuHURA Biosciences included in Russell 3000 and 2000 Indexes


TuHURA Biosciences Completes Acquisition of Kineta

Jun 30, 2025, 8:50 AM EDT - 1 year ago

TuHURA Biosciences Completes Acquisition of Kineta


TuHURA Biosciences initiated with a Buy at Brookline

2025-06-23T17:48:27.000Z - 1 year ago

TuHURA Biosciences initiated with a Buy at Brookline


TuHURA Biosciences Earnings release: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

TuHURA Biosciences Earnings release: Q1 2025


TuHURA Biosciences Quarterly report: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

TuHURA Biosciences Quarterly report: Q1 2025


TuHURA Biosciences Annual report: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

TuHURA Biosciences Annual report: Q4 2024


TuHURA Biosciences Earnings release: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

TuHURA Biosciences Earnings release: Q4 2024


TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.

Mar 11, 2025, 8:05 AM EDT - 1 year ago

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.


TuHURA Biosciences Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

TuHURA Biosciences Quarterly report: Q3 2024


2TrustHim
2TrustHim Jul. 13 at 6:59 PM
$HURA Is $2.60 Coming Back Before Close?
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 9 at 9:43 PM
$HURA Current Stock Price: $2.35
0 · Reply
2TrustHim
2TrustHim Jul. 9 at 8:27 PM
$HURA Form ARS!!!
2 · Reply
hhhhfdf
hhhhfdf Jul. 9 at 5:58 PM
$HURA Any updates, about new orphan drug status?
0 · Reply
TuHURA_IR
TuHURA_IR Jul. 6 at 2:42 PM
$HURA Our planned Phase 1b/2 study of TBS-2025 in AML combines two phases of clinical development into a single integrated trial. Dr. Craig Tendler, CMO consultant overseeing the TBS-2025 development program and TuHURA Board member, described the design in the June 15 announcement: "The FDA provided valuable feedback and comprehensive guidance on trial design, which we incorporated into our proposed Phase 1b dose optimization trial. Our plan is to combine the Phase 1b with the Phase 2 study for a combination study design that is much more efficient and could potentially save 4-6 months in development time." We anticipate FDA written responses in July 2026 and, depending on those responses, are targeting initiation of the trial in the second half of 2026.
0 · Reply
Gotsomescrewsmissing
Gotsomescrewsmissing Jul. 4 at 1:21 PM
$PLUG $FLY $HURA worth watching Texas Stock Exchange to launch trading Monday https://share.google/LyvdsxhtkUclEjNQJ
0 · Reply
TuHURA_IR
TuHURA_IR Jul. 2 at 1:52 PM
$HURA In AML patients with NPM1 mutations, VISTA expression has been associated with low response rates of short duration following current therapies, including recently approved menin inhibitors. The June 15 IND filing for TBS-2025 is designed to study whether blocking VISTA can change those outcomes. As President and CEO Dr. James Bianco described in the announcement: "Currently, there are no approved or effective treatment options for these patient populations, representing a significant unmet medical need." We are targeting initiation of the Phase 1b/2 study in the second half of 2026, following FDA written responses anticipated in July 2026.
0 · Reply
TuHURA_IR
TuHURA_IR Jun. 30 at 8:48 PM
$HURA Our pipeline now extends from Merkel Cell Carcinoma into AML and other blood-related cancers, with TBS-2025 targeting VISTA-driven immune evasion alongside our ongoing IFx-2.0 program. On June 15, we filed an Investigational New Drug application with the FDA for TBS-2025, our VISTA-inhibiting antibody, in molecularly defined subsets of acute myeloid leukemia (AML) and other blood-related cancers. The IND covers patients with NPM1 mutations and, in the future, those with FLT3-ITD mutations. It will also enroll patients with relapsed/refractory high-risk myelodysplasia (MDS), where VISTA expression has been associated with low response rates. This filing advances our development in a setting of significant unmet medical need.
0 · Reply
AdityaP
AdityaP Jun. 29 at 3:31 PM
$HURA ESMO
0 · Reply
StocksandRealEstate
StocksandRealEstate Jun. 29 at 12:43 PM
$HURA cmon you dirty dog
0 · Reply
AnalyticaInvestor
AnalyticaInvestor Jun. 29 at 10:15 AM
$FBIZ Good morning, investors. Agricultural and food producers continue benefiting from structural demand and government support, while miners remain in focus as investors position around critical commodity supply chains. On the watchlist, $FBIZ continues trading near 52 week highs with strong insider alignment and solid YTD performance. Among gainers, $LVWR jumped 37%, while $PYXS and $DOMO also posted strong advances. On the downside, $HURA fell 17% despite no clear company specific catalyst. Read the full Analytica Alpha 👇 https://analyticainvestor.beehiiv.com/p/biotech-miners-lead-move
0 · Reply
PastaSlobCFA
PastaSlobCFA Jun. 26 at 9:15 PM
$HURA What happened?
0 · Reply
uglyflint
uglyflint Jun. 26 at 6:57 PM
$HURA criminal scum shorts.
0 · Reply
Gotsomescrewsmissing
Gotsomescrewsmissing Jun. 26 at 6:33 PM
$HURA #legacykintrashareholder
0 · Reply
jayyflash
jayyflash Jun. 26 at 6:24 PM
$HURA 13% down for no reason other than manipulation with Shorting on a Friday. Getting away with criminal activities because they can. Why should anyone be in this kind of a stock market for you to steal people’s money and have them stuck . Fair market trading or no trading. Cheaters not allowed
0 · Reply
2TrustHim
2TrustHim Jun. 24 at 5:52 PM
$HURA $3.50 Algorithmic Move Closing In!!!
0 · Reply
mhaven2020
mhaven2020 Jun. 23 at 4:57 PM
$ELDN update day 44. I like to watch and see how transactions and level 2's affect the price and speculate the next moves. Time and Sales . Into $HURA, $CREX, $ATLN, $ADTX, and a few other tickers all pretty light so far. Day 1 on ATLN, ADTX, day 2 on HURA and CREX. Follow for more. Here, on X and YouTube.
0 · Reply
Stock__Hunter
Stock__Hunter Jun. 23 at 10:25 AM
$HURA Simple trend lines is all you need some times.
0 · Reply
2TrustHim
2TrustHim Jun. 22 at 7:53 PM
$HURA Inching Higher And Higher!!!
0 · Reply
mhaven2020
mhaven2020 Jun. 22 at 3:20 PM
$ELDN Hopefully you played along. I have been here a month and a half. I am updating my notes and blending this data into my calibrations. Daily RSI approaching resistance. This could consolidate back down to 4.20 or a bit less pretty easy. Be ready to grab some more on the dip if you area long term holder. I still have around 250 shares tied up up here even after my small exit @ 5% of my holdings exited at 20%. Follow for more! $HURA $CREX for the next month (DAY 1 on each).
0 · Reply
mhaven2020
mhaven2020 Jun. 22 at 2:49 PM
$CREX dropping in here too. Day 1 light entries. $ELDN day 43 . 1st exit at 4.17 hit. Closing 5% of holding to lock profits. Maintain heavy position. Transitioning in $HURA day 1
0 · Reply